Response of diffuse large B‐cell lymphoma treated with R‐CHOP and prognostic factors associated: A single institution analysis in Lima, Peru
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2439_79
Abstract: GCB and 34 CD5(+)/CD10(‐) non‐GCB DLBCL. Karyotype was successfully assessed in 43%, BCL2, BCL6, MYC abnormalities were found in 65%, 30%, and 26% in CD5(+)/CD10(+), and in 66%, 70%, and 23% in CD5(+)/CD10(‐), respectively, of… read more here.
Keywords: cd5; cd5 cd10; cd5 dlbcl; response ... See more keywords
Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell Iymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7561
Abstract: 7561Background: CD5+ DLBCL comprises 5-10% of DLBCL and is characterized by various aggressive clinical features and frequent CNS relapse. Our previous retrospective study (Miyazaki et al. Ann Onco... read more here.
Keywords: cd5; dose adjusted; cd5 dlbcl; study ... See more keywords